Table 2.

Multivariable analysis of cause-specific survival for women with uterine adenosarcoma, endometrial stromal sarcoma, and leiomyosarcoma (n = 9410).

Type of sarcoma	Uterine adenosarcoma (n = 994)				Endometrial stromal sarcoma (n = 2910)				Uterine leiomyosarcoma (n = 5506)
	Survival rate		Multivariable		Survival rate		Multivariable		Survival rate		Multivariable
Characteristic	No.	5-yr (%)	HR (95%CI)	P-value	No.	5-yr (%)	HR (95%CI)	P-value	No.	5-yr (%)	HR (95%CI)	P-value
Age (y)
≥60	480	76.0	1.29 (0.96–1.74)	0.09	923	51.3	1.38 (1.19–1.61)	<0.001	1671	35.1	1.53 (1.41–1.66)	<0.001
<60	514	83.8	1		1987	79.6	1		3835	54.3	1
Ethnicity
Caucasian	652	81.2	1		1891	71.0	1		3420	51.1	1
African American	131	73.1	1.18 (0.79–1.77)	0.42	394	59.2	1.26 (1.05–1.52)	0.01	950	41.7	1.37 (1.24–1.51)	<0.001
Hispanic	113	80.8	1.32 (0.82–2.14)	0.26	357	77.8	1.05 (0.82–1.35)	0.68	674	47.5	1.05 (0.93–1.19)	0.47
Others	98	81.9	0.91 (0.54–1.52)	0.71	268	78.4	0.99 (0.75–1.31)	0.97	462	46.6	1.12 (0.98–1.30)	0.11
Marital status
Single	194	80.9	1		489	66.6	1		1020	45.6	1
Married	488	85.2	0.98 (0.64–1.49)	0.91	1647	75.9	0.75 (0.62–0.90)	0.003	3080	52.7	0.83 (0.75–0.92)	<0.001
Others	312	71.4	1.43 (0.93–2.19)	0.11	774	62.4	0.92 (0.74–1.14)	0.43	1406	42.2	0.99 (0.89–1.12)	0.97
Registry Area
West	525	81.3	1		1498	73.5	1		2849	46.2	1
Central	193	75.7	1.24 (0.85–1.81)	0.27	708	67.6	1.09 (0.92–1.29)	0.32	1239	51.5	0.93 (0.84–1.03)	0.14
East	276	80.9	1.17 (0.81–1.67)	0.40	704	68.6	0.98 (0.82–1.17)	0.81	1418	51.4	0.82 (0.75–0.90)	<0.001
Year at diagnosis
1973–1999	236	83.3	1		946	73.9	1		1979	54.7	1
2000–2009	523	79.2	1.30 (0.91–1.88)	0.16	1383	71.4	1.05 (0.87–1.26)	0.68	2406	44.7	1.07 (0.97–1.18)	0.17
2010–2012	235	n.r	1.07 (0.64–1.80)	0.78	581	n.r.	1.23 (0.97–1.54)	0.08	1121	n.r.	0.98 (0.86–1.13)	0.82
Grade
1	109	93.4	1		465	96.1	1		314	81.8	1
2	158	84.2	2.59 (1.14–5.87)	0.02	926	94.3	1.34 (0.87–2.07)	0.18	573	66.7	1.82 (1.40–2.36)	<0.001
3a	173	54.8	7.37 (3.41–15.9)	<0.001	914	32.6	14.0 (9.49–20.7)	<0.001	2003	32.7	4.64 (3.68–5.86)	<0.001
Unknown	554	83.9	2.43 (1.17–5.05)	0.02	605	69.1	4.52 (3.02–6.75)	<0.001	2616	52.3	2.72 (2.17–3.42)	<0.001
Tumor size
≤5.0 cm	268	87.7	1		636	87.3	1		608	69.8	1
>5.0 cm	318	64.7	1.89 (1.28–2.80)	0.001	1084	61.2	1.91 (1.50–2.43)	<0.001	3096	42.2	2.03 (1.74–2.35)	<0.001
Unknown	408	86.2	0.79 (0.51–1.24)	0.31	1190	70.5	1.36 (1.06–1.76)	0.016	1802	52.0	1.62 (1.37–1.91)	<0.001
Lymph node status
Negative	848	81.8	1		2006	76.8	1		3561	49.0	1
Positive	29	43.0	2.34 (1.29–4.25)	0.01	192	30.4	2.43 (1.99–2.98)	<0.001	188	20.9	2.10 (1.75–2.52)	<0.001
Unknown	117	75.8	1.71 (1.06–2.74)	0.03	712	65.4	1.67 (1.37–2.03)	<0.001	1757	50.4	1.21 (1.09–1.35)	<0.001
Surgery type
No surgery	46	59.1	4.70 (1.85–11.9)	0.001	293	34.5	2.82 (2.08–3.82)	<0.001	466	18.9	4.09 (3.42–4.88)	<0.001
Total/pan/simple hyst	720	82.2	1		1848	76.8	1		3383	50.6	1
Others	228	78.0	1.28 (0.90–1.80)	0.17	769	69.6	1.17 (0.98–1.40)	0.08	1657	52.1	1.20 (1.09–1.33)	<0.001
Radiation
No adjuvant radiation	746	76.7	1		1850	77.9	1		3335	49.9	1
Adjuvant radiation	117	74.6	1.06 (0.74–1.52)	0.75	493	65.8	0.91 (0.76–1.09)	0.30	871	48.4	0.97 (0.88–1.08)	0.58
Others	77	65.7	0.82 (0.37–1.83)	0.64	567	52.3	0.99 (0.76–1.29)	0.94	1300	45.9	0.86 (0.74–0.99)	0.04

A Cox proportional hazard regression model for multivariable analysis adjusted for collected covariates (myometrial invasion was not included due to over 50% of lack of data and stage was excluded for the multicollinearity of other factors). Significant P-values are emboldened.

Abbreviations: n.r., cases did not reach 5-year follow-up; 5-yr, 5-year proportion; and hyst, hysterectomy.

^aIncluded undifferentiated type.